Multicenter phase II study with docetaxel, 5-FU, leucovorin, and oxaliplatin in patients with metastatic or locally advanced gastric cancer or cancer of the esophagogastric junction- FLOT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-004135-22-DE

Enrollment

Registered

2005-11-08

Start date

2006-01-31

Completion date

Unknown

Last updated

2013-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic or locally advanced gastric cancer

Interventions

Product Name: not applicable Product Code: not applicable Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Taxotere 80mg Konzentrat und Lösungsmittel zur Herstellung e

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced gastric cancer Sufficient bone marrow and organ function Age >= 18 years; women and men ECOG 0, 1, or 2 written informed concent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Known allergy to any study drug Participation at another clinical investigation Severe concurrent illness Gravidity

Design outcomes

Primary

Measure	Time frame
Main Objective: Response rate ;Secondary Objective: Safety Time To Progression (TTP) Overall survival;Primary end point(s): Response rate	—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026